Medicines Australia welcomes new chair and members of the Pharmaceutical Benefits Advisory Committee

Medicines Australia is pleased to welcome the appointment of Professor Andrew Wilson as incoming Chair of the Pharmaceutical Benefits Advisory ...

Read more →

Simponi I.V. (golimumab) becomes first fully human anti-TNF infusion therapy approved for treatment of moderately to severely active rheumatoid arthritis

[:content [\2 \space \D \e \c \e \m \b \e \r \space \2 \0 \1 \3 \space \- \  \J \a \n \s \s \e \n \space \I \n \c \. \space \a \n \n \o \u \n \c \e \d \space \t \o \d \a \y \space \t \h \a \t \space \H \e \a \l \t \h \space \C \a \n \a \d \a \space \h \a \s \space \a \p \p \r \o \v \e \d \space \S \i \m \p \o \n \i \  \I \. \V \. \space \( \g \o \l \i \m \u \m \a \b \) \space \f \o \r \space \i \n \f \u \s \i \o \n \space \f \o \r \space \t \h \e \space \t \r \e \a \t \m \e \n \t \space \o \f " ..."]]
Read more →

Protalix announces Elelyso (taliglucerase alfa) approved in Canada for the treatment of Gaucher disease in both adult and pediatric patients

Protalix BioTherapeutics, Inc. announced today that Health Canada has granted regulatory approval to Elelyso (taliglucerase alfa for injection) for the long-term enzyme replacement therapy ...

Read more →

Better information needed on multiple myeloma drug

[:content [\1 \4 \space \M \a \r \c \h \space \2 \0 \1 \4 \space \- \  \N \I \C \E \space \h \a \s \space \i \s \s \u \e \d \space \n \e \w \space \d \r \a \f \t \space \g \u \i \d \a \n \c \e \  \o \n \space \t \h \e \space \u \s \e \space \o \f \space \l \e \n \a \l \i \d \o \m \i \d \e \space \( \R \e \v \l \i \m \i \d \, \space \C \e \l \g \e \n \e \) \space \f \o \r \space \t \r \e \a \t \i \n \g \space \t \h \e \space \b \l \o \o \d \space \c \a \n \c \e \r " ..."]]
Read more →

Cancer Drugs Fund a ‘missed opportunity’, says MP

Speaking exclusively to PMLiVE, Burstow said the Cancer Drugs Fund (CDF), which since 2010 has paid nearly £1bn extra into the NHS ...

Read more →

CADTH issues draft guidelines for manufacturers on application fees for the CADTH Common Drug Review

As communicated on May 13, 2014, effective September 1, 2014, CADTH will be introducing an industry application fee for submissions ...

Read more →

Battle in Australia over access to cancer drugs

Access to cancer drugs in Australia is coming to a head after a bitter tit for tat over a pharma ...

Read more →

$1.3 billion to list life-saving medicines

The Abbott Government will invest $1.3 billion listing new medicines and vaccines that will save lives and help thousands of ...

Read more →

Budget 2015: drug firms prepare for war

Drug companies are on the brink of war with the Abbott government over proposed cuts in next week’s budget, which ...

Read more →

Price disclosure 2015 April cycle outcomes summary

The summary of price disclosure price reductions for the 2015 April Cycle (Second SPD) has been published on the Price Disclosure page of ...

Read more →

Five ideas for the new NZ Health Minister

Our new Minister of Health, Dr Jonathan Coleman, has inherited a portfolio which has averaged expenditure increases of 4.2 per ...

Read more →

NICE consults on a new treatment for myelodysplastic syndromes

[:content [\N \I \C \E \  \h \a \s \space \i \s \s \u \e \d \space \n \e \w \space \d \r \a \f \t \space \g \u \i \d \a \n \c \e \  \t \h \a \t \space \d \o \e \s \space \n \o \t \space \r \e \c \o \m \m \e \n \d \space \l \e \n \a \l \i \d \o \m \i \d \e \space \( \R \e \v \l \i \m \i \d \) \space \f \o \r \space \t \r \e \a \t \i \n \g \space \p \a \t \i \e \n \t \s \space \w \i \t \h \  \m \y \e \l \o \d \y \s \p \l \a \s \t \i \c \space \s \y \n \d \r \o \m \e \. \space \  \F \o \r \space \m \o \r \e \space \d \e \t \a \i \l \s \, \space \g \o \space \t \o \  " ..."]]
Read more →

Cost of life under microscope as new cancer drug on wait list

How much is an extra year of life worth when you have a terminal disease? ...

Read more →

Health Minister abandons strategic agreement with Medicines Australia – medicines industry stability and patient safety at risk

Medicines Australia is extremely disappointed with a last-minute decision by Health Minister Sussan Ley to abandon a Strategic Agreement, which ...

Read more →

Confirmation of 1 April 2014 price disclosure prices and new price disclosure fact sheet

[:content [\1 \0 \space \M \a \r \c \h \space \2 \0 \1 \4 \space \- \  \C \o \n \f \i \r \m \a \t \i \o \n \space \o \f \space \1 \space \A \p \r \i \l \space \2 \0 \1 \4 \space \n \e \w \space \p \r \i \c \e \s \space \r \e \s \u \l \t \i \n \g \space \f \r \o \m \space \2 \0 \1 \4 \space \M \a \i \n \space \C \y \c \l \e \space \o \f \space \E \A \P \D \space \h \a \v \e \space \n \o \w \space \b \e \e \n " ..."]]
Read more →